Hepatitis B, rituximab, screening, and prophylaxis: effectiveness and cost effectiveness

J Clin Oncol. 2012 Sep 10;30(26):3155-7. doi: 10.1200/JCO.2012.43.7509. Epub 2012 Aug 13.
No abstract available

Publication types

  • Editorial
  • Comment

MeSH terms

  • Antibodies, Monoclonal, Murine-Derived / adverse effects
  • Antineoplastic Combined Chemotherapy Protocols / adverse effects*
  • Cost-Benefit Analysis*
  • Cyclophosphamide / adverse effects
  • Doxorubicin / adverse effects
  • Early Diagnosis*
  • Hepatitis B / diagnosis*
  • Hepatitis B / economics*
  • Humans
  • Lymphoma, Large B-Cell, Diffuse / economics*
  • Lymphoma, Large B-Cell, Diffuse / virology*
  • Prednisone / adverse effects
  • Rituximab
  • Vincristine / adverse effects

Substances

  • Antibodies, Monoclonal, Murine-Derived
  • R-CHOP protocol
  • Rituximab
  • Vincristine
  • Doxorubicin
  • Cyclophosphamide
  • Prednisone